US/UK/Canada

Share

Links

Quotes

Genetic Analysis GA-map® enables cost-efficient and reliable mapping and profiling of gut microbiota via In Vitro Diagnostics (IVD) testing. Genetic Analysis is currently the only company globally that offers a patented and CE-marked standardized testing platform for microbiome analysis, the GA-map® Dysbiosis Test. GA has initiated an ambitious growth plan to rapidly grow the business over the next few years in the EU and US. We have proven our existing business model to molecular labs, and the Company is now ready, with the CE-marked GA-map®, to be commercialized in the current market for microbiota testing as well as to enter the market for companion diagnostics, where the test will be performed in combination with microbiota altering drugs. The growth plan will expand the commercialization through carefully selected distributors for vast expansion and strategic direct sales of the current product portfolio within Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD). Based on the competitive advantages that a standardized diagnostic platform will have in the microbiota field, compared to the current research-based tools, and the huge number of potential patients, we assess that the market for GA’s technology is significant.
Ronny Hermansen, CEO
GA accomplished essential milestones during the period by being granted patents in US, Japan, India and the EU. In June, we successfully completed the next generation of the GA-map® Dysbiosis Test with a CE mark. The next generation includes a built-in bacteria functionality reporting algorithm that will further reduce run-time for the lab. We expanded our distribution network with Eagle Bioscience in the US and reached a significant agreement with a lab chain in Germany to sell the GA-map® platform installation package. Finally – GA, together with the Norwegian University of Life Sciences, is developing the world’s first complete database of reference genomes, HumGut, a collection of about 30,000 genomes, covering the broad diversity of bacterial genomes found in the human gut. Mapping and unlocking the genes present in a healthy gut is instrumental for developing new diagnostics and better treatment regimes. We will actively use this powerful search engine and database to identify novel gut signatures which we can plug onto our GA map® technology platform to develop new innovative diagnostic markers within the microbiome field.
Ronny Hermansen, CEO
Pick a time period -
Tags ( Active)

Publication of interim report January – March 2026

OSLO, NORWAY – May 28, 2026: Genetic Analysis AS ("GA" or the "Company") hereby publishes the interim report for the period January – March 2026. The report is available as an attached file to this release and on the Company's website. Below is a summary of the report.Ronny Hermansen, CEO of Genetic Analysis, comments:“The first quarter of 2026 was marked by continued progress for Genetic Analysis, with strong growth in recurring GA-map[®] kit sales and further advancement of our microbiome-based diagnostics pipeline. The development confirms the relevance of our standardized GA-map[® ]

Minutes of Annual General Meeting

OSLO, NORWAY – 20 May 2026: The Annual General Meeting in Genetic Analysis AS (the "Company") was held on Wednesday 20 May 2026 at 15:00 hours (CEST) at the Company's premises in Ulvenveien 80B, Oslo.1. Opening of the meeting The meeting was opened by chairperson Morten Jurs, who recorded the list of attending shareholders. In total 23,896,887 shares out of the Company's 69,087,041 shares were present, corresponding to 34.59% of the total number of shares and votes of the Company. 2. Election of a chairperson and a person to co-sign the minutes Chairperson Morten Jurs was elected

Genetic Analysis granted a U.S. patent for companion diagnostic related to IBS treatment response

OSLO, NORWAY – 7 May 2026: Genetic Analysis AS (“GA” or “the Company”) announces today the United States Patent And Trademark Office (USPTO) has granted U.S. patent no. 12,596,121, titled “COMPANION DIAGNOSTIC METHOD FOR USE IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIETARY INTERVENTIONS OR FAECAL MICROBIOTA TRANSPLANT”. The patent covers a diagnostic method designed to assess the likelihood that patients with Irritable Bowel Syndrome (IBS) will respond to treatment with a low-FODMAP diet or Faecal Microbiota Transplant (FMT).IBS is a common gastrointestinal disorder affecting an

Notice of annual general meeting

OSLO, NORWAY – 5 May 2026: Notice is hereby served that the annual general meeting in Genetic Analysis AS (the "Company") will be held on Wednesday 20 May 2026 at 15:00 hours (CEST) in the Company's premises in Ulvenveien 80B, Oslo.Shareholders are encouraged to submit a proxy with voting instructions prior to the general meeting, see Appendix 2. Shareholders that still wish to participate in the general meeting by person are encouraged to notify the Company as stipulated in Appendix 1. Agenda: 1. Opening of the meeting by the chairman of the board 2. Election of a chairperson and

Genetic Analysis to attend DDW congress in Chicago

OSLO, NORWAY, April 30, 2026: Microbiome DX company Genetic Analysis AS (“GA”) announces its attendance at Digestive Disease Week (DDW) congress in Chicago, May 3 – May 5 2026. The company will use the meeting to highlight its upcoming product, GA-map® IBD Precision Dx, a next-generation diagnostic solution for personalized management in inflammatory bowel disease (IBD).DDW offers an opportunity to gain the latest insights in the Gastrointestinal field, while providing valuable networking and partnering opportunities. Genetic Analysis’ Head of Commercial, Kari Furu, Christina Casén, SVP

Genetic Analysis AS launches AInsight for AI-assisted interpretation of GA-map® Dysbiosis Test results

OSLO, NORWAY – March 12: Genetic Analysis AS (“GA” or “the Company”) today announces the launch of GA-map® Dysbiosis Test AInsight (“AInsight”), an AI-assisted interpretation platform designed to translate microbiome analysis results into structured and clinically relevant insights, supporting broader adoption of microbiome testing in clinical practice.The GA-map® Dysbiosis Test is a CE-marked molecular diagnostic assay designed to profile gut microbiome and evaluate intestinal dysbiosis by comparing a patient’s microbiome profile to a healthy reference population. While microbiome analysis

Publication of year-end report 2025

OSLO, NORWAY – February 27, 2026: Genetic Analysis AS ("GA" or the "Company") hereby publishes the year-end report for 2025. The report is available as an attached file to this release and on the Company's website. Below is a summary of the report.Ronny Hermansen, CEO of Genetic Analysis, comments:“The fourth quarter reflects continued execution of our long-term growth strategy, with progress in both commercial expansion and product development. We are advancing collaborations with industry partners, further strengthening the position of GA-map® technology in microbiome-related clinical

Clarification regarding the publication date of the year-end report 2025

OSLO, NORWAY – February 26, 2026: Genetic Analysis AS (“GA” or “the Company”) announces that the year-end report for 2025 will be published on Friday, 27 February 2026.The Company’s financial calendar for 2025 was included in the interim report for the first quarter of 2025, in which it was stated that the year-end report for 2025 would be published on 27 February 2026. This date has also been published on the Company’s website and on Spotlight Stock Market’s company page. However an incorrect publication date (25 February 2026) was stated in the interim report for the third quarter of

Genetic Analysis AS further strengthens IP portfolio with patent approval in the United States

OSLO, NORWAY – February 19, 2026: Genetic Analysis AS (“GA” or “the Company”) announces that its patent application US2017/0369941 has been allowed for grant by the United States Patent and Trademark Office (USPTO). The patent, entitled “METHOD FOR PREVENTING FALSE POSITIVES IN METHODS EMPLOYING DDNTP’S”, strengthens the protection of GA’s proprietary diagnostic technology. GA maintains an active patent strategy covering all major geographical markets and has previously announced approval in the EU and other countries for this patent.CEO Ronny Hermansen comments:”High analytical accuracy

Microbiome Dx Genetic Analysis announces important patent approval enhancing the use of GA-map® in Canada

OSLO, NORWAY – February 12, 2026: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces that its important patent application CA2980637) has now been allowed for grant in Canada.  The important patent entitled “METHOD FOR DETERMINING GASTROINTESTINAL TRACT DYSBIOSIS” covers the Company’s unique algorithm incorporated in the GA-map® technology for profiling gut microbiota. GA has an active patent strategy covering all major geographical markets and has previously announced approval in EU, China and other countries for this patent.The subject matter of this family of

Publication of interim report Q3 2025

OSLO, NORWAY – November 27, 2025: Genetic Analysis AS ("GA" or the "Company") hereby publishes the interim report for Q3, and the first nine months of 2025. The report is available as an attached file to this release and on the Company's website. Below is a summary of the report.Ronny Hermansen, CEO of Genetic Analysis, comments:“The third quarter was marked by consistent progress across Genetic Analysis’ commercial and development activities, underscoring continued execution on our long-term growth strategy. The third quarter was influenced by the slower summer holiday period, but sales

Genetic Analysis AS announces milestone in the IBD diagnostic test development project - completion of biomarker panel for GA-map® IBD Precision Dx

OSLO, NORWAY – 17 November 2025: Microbiome DX company Genetic Analysis AS (“GA”) is pleased to announce the completion of the biomarker panel development in its ongoing IBD Precision Dx project. This marks a major milestone in the project, with GA now progressing to the final validation phase and completion of the software development.The goal of the IBD Precision Dx project is to develop a microbiome-based diagnostic test capable of predicting disease course in Ulcerative Colitis (UC) patients, thereby supporting earlier and more targeted treatment decisions. The project is conducted in

Genetic Analysis attends the Biomarkers & Precision Medicine congress in London

OSLO, NORWAY, September 26, 2025: Microbiome DX company Genetic Analysis AS (“GA”) announces its attendance at the Biomarkers & Precision Medicine congress in London, 30 September - 01 October 2025. The event offers a chance to gain the latest insights from across the biomarker and precision medicine landscape, while providing valuable networking and partnering opportunities.Genetic Analysis’ Head of Commercial, Kari Furu, will attend the congress. GA will use the event to highlight GA's microbiome testing platform, GA-map®, demonstrating how it can be used in the development of new

Genetic Analysis AS launches the GA-map® MHI GutHealth reagent kit

OSLO, NORWAY – 24 September 2025: Microbiome DX company Genetic Analysis AS (“GA”) announces the launch of a novel Research Use Only (RUO) reagent kit, the GA-map® MHI GutHealth. The test provides an advanced tool for measuring antibiotic-induced microbiome imbalances and has been validated for recurrent Clostridioides difficile infection (rCDI). With this launch, GA-map® MHI GutHealth is made available for Luminex xMAP® users globally.As communicated on December 20, 2024, GA and Ferring Pharmaceuticals announced a collaboration to develop a new microbiome diagnostic test. Since then, GA

Publication of Half-year report 2025

OSLO, NORWAY – August 27 2025: Genetic Analysis AS ("GA" or the "Company") hereby publishes the half-year report for H1, and April - June 2025. The Half-year report is available as an attached file to this release and on the Company's website. Below is a summary of the report.Ronny Hermansen, CEO of Genetic Analysis, comments: “The first half of 2025 has reinforced the growing interest in our products and service for microbiome diagnostics across clinical, pharmaceutical, and consumer health sectors. This development reflects a broader recognition of the microbiome’s role in health and

Genetic Analysis AS and Pangea Laboratory LLC announces the launch of GA-map® MHI GutHealth in the USA

OSLO, NORWAY/IRVINE, CA, USA – 29 July 2025: Microbiome DX company Genetic Analysis AS (“GA”) and Pangea Laboratory LLC (“Pangea”) announces the launch of the GA-map® MHI GutHealth as a Research Use Only (RUO) test in the USA. As part of the collaboration Pangea will perform analysis in their CLIA-certified, CAP-accredited laboratory in Tustin, California.The GA-map® MHI GutHealth is the first microbiome-based diagnostic test providing clinically actionable insights into antibiotic-induced microbiome imbalances. The test has been developed by GA in collaboration with Ferring Pharmaceuticals

Genetic Analysis subsequent offering to existing shareholders has now been registered with the Norwegian Register of Business Enterprises

Genetic Analysis AS' (“GA” or the “Company”) subsequent offering to existing shareholders, for which the subscription period ended on June 16, 2025 (the "Subsequent Offering"), has now been registered with the Norwegian Register of Business Enterprises (No. Foretaksregisteret).During the period June 5 – June 16, 2025, GA carried out the Subsequent Offering that provided the Company with approximately NOK 4.1 million by issuance of 4,813,194 new shares, before issue costs. The Subsequent Offering has now been registered with the Norwegian Register of Business Enterprises. After this, the

Genetic Analysis announces final outcome of the subsequent offering to existing shareholders

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED BY SWEDISH OR NORWEGIAN LAW. On June 16, 2025, Genetic Analysis AS' (“GA” or the “Company”) announced the preliminary outcome of the Company’s subsequent offering with gross

Genetic Analysis: Direct issue has now been registered with the Norwegian Register of Business Enterprises

OSLO, NORWAY - June 18, 2025: Microbiome DX company Genetic Analysis AS ("GA" or the "Company") hereby announces that the direct issue which was announced in a press release on the 05.05.2025 and approved by the Annual General Meeting on 19.05.2025 has now been registered with the Norwegian Register of Business Enterprises (No. Foretaksregisteret).The directed issue provided the Company with approximately NOK 12.8 million by issuance of 14 890 576 new shares, before issue costs. The direct issue has now been registered with the Norwegian Register of Business Enterprises. After this, the

Genetic Analysis announces preliminary outcome of the subsequent offering to existing shareholders

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED BY SWEDISH OR NORWEGIAN LAW. The subscription period in Genetic Analysis AS' (“GA” or the “Company”) subsequent offering with gross proceeds of up to approximately NOK 7.1

Genetic Analysis AS: Mandatory notification of trade

OSLO, NORWAY – 12 June 2025: Genetic Analysis AS (“GA” or “the Company”) announces that members of the Board and Management have subscribed for shares in the ongoing share offering in GA.Tore Grøttum, Interim CFO in Genetic Analysis AS, has today including oversubscription subscribed for 200.000 new GEAN-shares at a price of 0.86 NOK per share. Tore Grøttum will, following the transaction and provided that the oversubscribed shares are allocated, own 1,834,840 shares following the transaction.

Today is the last day for trading in the subscription rights for subscribing for shares in Genetic Analysis

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED BY SWEDISH OR NORWEGIAN LAW. Today, June 12, 2025, is the last day for trading in subscription rights for subscribing for shares in Genetic Analysis AS' (“GA” or the “Company”)

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe